Hoth Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.01.25	Why Is Hoth Therapeutics Stock Flying Higher On Tuesday? (Benzinga)
26.12.24	Why Hoth Therapeutics Is Rising In Pre-market? (RTTNews)
17.09.24	Hoth Therapeutics Reports Encouraging Pre-clinical Data For Its Alzheimer's Drug; Stock Up (RTTNews)
05.09.24	Hoth Stock Soars On Announcement Of Positive Data For HT-001 In EGFRI-Associated Skin Toxicities (RTTNews)
15.08.24	Hoth, Aronnax Enter Master Services Agreement For HT-KIT Therapeutic - Quick Facts (RTTNews)
24.07.24	Hoth Signs Deal With LTS Therapy To Develop & Manufacture HT-ALZ Oral Film Prot; Stock Up (RTTNews)
19.03.24	Why Is Alzheimer's-Focused Hoth Therapeutics Stock Trading Higher On Tuesday? (Benzinga)
19.03.24	Hoth Therapeutics: Pre-clinical Research Shows HT-ALZ's Profound Impact On Alzheimer's Pathology (RTTNews)
26.02.24	Hoth Therapeutics Partners Altasciences For Study On HT-KIT Cancer Treatment (RTTNews)
18.01.24	Hoth Therapeutics Received FDA Clearance To Broaden HT-001 Clinical Trial (RTTNews)
27.12.23	Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami (PR Newswire)
05.12.23	Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies (PR Newswire)
14.11.23	Hoth Completes Pre-IND Meeting With FDA On Development Of HT-KIT Therapeutic (RTTNews)
14.11.23	Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT (PR Newswire)
10.11.23	Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023 (PR Newswire)
05.10.23	Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery (PR Newswire)
02.10.23	Hoth Therapeutics: FDA Grants Pre-IND Meeting For HT-KIT; Stock Surges (RTTNews)
02.10.23	FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients (PR Newswire)
15.09.23	Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (PR Newswire)
13.09.23	Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (PR Newswire)
13.09.23	Hoth Therapeutics Reports Positive Preclinical Results Of HT-KIT Therapeutic; Stock Surges (RTTNews)
13.09.23	Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia (PR Newswire)
11.09.23	Hoth Therapeutics' Pre-IND Submission For HT-KIT For Advance Systemic Mastocytosis Accepted By FDA (RTTNews)
11.09.23	Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients (PR Newswire)
06.09.23	Hoth Therapeutics Reports Positive Results From Phase 1b Trial Of BioLexa (RTTNews)
06.09.23	Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa (PR Newswire)
09.08.23	Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease (PR Newswire)
25.07.23	Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial (PR Newswire)
19.07.23	Hoth Receives Protocol Approval For HT-001 Cancer Therapeutic; Stock Up (RTTNews)
19.07.23	Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic (PR Newswire)
14.06.23	Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site (PR Newswire)
07.06.23	Pre-market Movers: CJET, MOND, YEXT, CD, NAMS… (RTTNews)
06.06.23	Hoth Therapeutics' Alzheimer's Disease Drug Yields Positive Results In Preclinical Study (RTTNews)
06.06.23	Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease (PR Newswire)
12.05.23	Hoth Therapeutics and Algorithm Sciences Terminate Letter of Intent to Merge (PR Newswire)
27.04.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, SPPI, HOTH (PR Newswire)
26.04.23	Hoth Therapeutics Intends To Merge With Algorithm Sciences (RTTNews)
26.04.23	Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge (PR Newswire)
08.03.23	Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy (PR Newswire)
16.02.23	Hoth Therapeutics Retains ShareIntel to Investigate Illegal Naked Shorting Activity (PR Newswire)
08.02.23	Hoth: Proof-of-concept Data In Mouse Model Supports Therapeutic Cognitive Potential Of HT-ALZ (RTTNews)
08.02.23	Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ (PR Newswire)
25.01.23	Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy (PR Newswire)
03.01.23	Hoth Therapeutics Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire)
30.12.22	Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire)
29.12.22	Hoth Therapeutics Rises On FDA Accepting IND For Its HT-001 Therapeutic (RTTNews)
29.12.22	Hoth Therapeutics Says FDA Accepts IND Application For HT-001 For Treatment Of Cancer Disorders (RTTNews)
29.12.22	Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy (PR Newswire)
01.12.22	Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’285.50	1.34 %	K V
Holcim	88.82	0.84 %	K V
Roche Hldg G	266.50	0.79 %	K V
ABB	49.75	0.55 %	K V
Novartis	90.57	0.20 %	K V
Alcon	76.52	-0.91 %	K V
Sonova Hldg	295.00	-1.01 %	K V
Zurich Insur Gr	546.00	-1.05 %	K V
Logitech Intl	78.68	-1.50 %	K V
Geberit	505.00	-1.67 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Hoth Therapeutics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten